The recently published DAISY trial investigating the efficacy of T-DXd in metastatic breast cancer patients with variable HER2 expression has increased the interest in presenting detailed information on HER2 biomarker levels in clinical trials, and stakes have been raised to improve the speed of HER2 assessment in routine pathology [46]. This evidence concerns the gene ERBB2 and breast cancer.